Changes in Hong Kong stocks | Goodwill B (02256) opened more than 6% ABSK211's phase I clinical trial and completed the first patient administration

The Zhitong Finance App learned that Heyu-B (02256) opened more than 6% higher. As of press release, it rose 6.53% to HK$9.875, with a turnover of HK$221,000.

According to the news, on August 31, Heyu B issued an announcement. Shanghai Heyu Biomedical Technology Co., Ltd. (“Heyu Pharmaceutical”), a subsidiary of the company, announced that it has completed the first patient administration of its phase I clinical trial of absk211, an oral, high-efficacy, small-molecule Pan-KRAS inhibitor that covers a wide range of CRAs changes in the treatment of advanced solid tumors with changes in the Kras gene.

Previously, the new drug clinical trial (IND) application for ABSK211, an oral, high-potency, and highly selective small molecule Pan-KRAS inhibitor being developed by the company to treat patients with advanced solid tumors with changes in the KRAS gene was approved by the US Food and Drug Administration (FDA). Preclinical study results show that ABSK211 has shown positive anti-tumor activity and good selectivity in both single drug and combination treatment scenarios, and is expected to provide new treatment options for solid tumor patients with KRAS gene changes.